Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack | D. Schadendorf | R. Sullivan | K. Flaherty | L. Fattore | R. Mancini | M. Pisanu | G. Madonna | D. Mallardo | G. Botti | P. Ascierto | G. Ciliberto | R. Baumgartner | M. Cantile | T. Kirchhoff | A. Ribas | D. Carbone | S. Costantini | A. Tsirigos | E. Simeone | S. Demaria | A. Thompson | L. Butterfield | C. Garbe | M. Mandalà | T. Crook | P. Szlosarek | D. Fenyo | P. Rutkowski | R. Rosell | L. Demidov | I. Osman | A. Pavlick | K. Lewis | M. Maio | N. Varadarajan | A. Frey | C. Proby | N. Syed | S. Formenti | Yibing Yan | M. Pacold | V. Ventura | A. Budillon | A. Forschner | A. Mackiewicz | M. Wongchenko | K. Giles | M. di Bonito | R. Bartz | A. Cesano | M. Zollo | P. Maiolino | M. Merlano | U. Moran | J. Weber | Genny Del Zotto | A. Giménez-Capitán | C. M. Cristiani | E. Carbone | N. Restifo | D. Giannarelli | T. Gajewski | A. Greco | R. Matin | C. Harwood | N. Karachaliou | Rossana Tallerico | M. Carotenuto | Veronica Ferrucci | D. Spano | C. Chiarolla | A. Moretta | A. Guminski | D. Rodríguez-Abreu | I. Márquez-Rodas | Zhiya Yu | I. Bondarenko | M. Molina-Vila | T. Eigentler | A. Drozdowskyj | A. Tzakos | D. Vivenza | S. Agarwala | M. Krogsgaard | M. Capone | Shi Zhong | S. Warren | Van Ren Sim | C. Sorrentino | G. Crespo | Hua Zhou | Ivan Liadi | F. Capone | F. Carrozza | F. Hermann | L. Lattanzio | A. Grimaldi | S. Morello | A. Eggermont | S. Hamm | A. Evans | A. Pinto | E. Pérez-Ruiz | K. He | William Rittase | D. Brocco | M. De Tursi | B. Simmons | C. Nigro | M. Ascierto | E. Gulletta | U. Keim | T. Amaral | K. O’Neill | A. Bretz | R. D'Aniello | M. Gowen | P. Bosio | Victoria Fang | R. Blanco | Cinzia Garofalo | A. Gatta | Kaitao Li | E. Gambale | A. Sorice | D. Liguoro | R. Ferguson | V. Vanella | M. Occelli | A. Pérez-García | T. Wulff | C. Fleming | A. Renziehausen | T. Tramontano | C. Varamo | Santiago Viteri Ramírez | C. Teixidó | F. Tonissi | C. Herbert | C. Ye | G. Hooper | G. Goodman | G. Sciancalepore | Matjaž Vogelsang | Francesco Paolo Pennino | Roberto Siciliano | Fatemeh Asadzadeh | S. Algarra | E. Aldeguer | M. A. Royo | G. Giglio | F. Fratangelo | C. Cauchi | Duane Moogk | C. Carella | Hexiao Wang | L. Di Lullo | B. Mark Smithers | Elina Staaf | Zhou Yuan | K. Kronthaler | S. Schrepfer | U. Parnitzke | Luisa Dassi | Vandenbussche Jonathan | Gevaert Kris | I. Tampouri | B. Rao | L. Weir | Su Li | D. Simpson | Carlos N. Martinez | E. Kazlow | A. D’Avino | Licia Guida | Augusto Cosacco | M. R. Sarno | I. Palazzo | G. Acunzo | M. De Fina | Antonia Silvestri | M. Specchia | M. Musacchio | Gian Marco De Maddi | M. Rovera | Z. Seia | S. Palazzini | F. Errico | D. Basso | L. Quaranta | G. Forte | F. Lavagna | S. Violante | J. Tchack | S. Paschke | R. Falcone | Astrid Ammendola | Bulotta Alessandra | Mirabile Aurora | L. Chiara | M. Raffaele | Parolini Danilo | Rizzo Nathalie | Martella Stefano | Modorati Giulio | Brianti Pina | Cestone Enza | Bellinzona Federica | Miserocchi Elisabetta | G. Luca | Gregorc Vanesa | Axel Haushild | Eric Watcher | Andrea Cerri | M. González-Cao | V. Ferrucci | F. Asadzadeh | R. Siciliano | C. Vanpouille-Box | C. F. Ruggiero | C. Zhu | M. Wilson | T. Puertolas | Scott Paschke | Janna Dougherty | A. Di Napoli | Adele Venturelli | Colombo Letizia | E. Selinger | Bhavya Rao | C. L. Nigro

[1]  G. Miccinesi,et al.  Assessing unmet needs in patients with cancer: An investigation of differential item functioning of the Needs Evaluation Questionnaire across gender, age and phase of the disease , 2017, PloS one.

[2]  G. Madonna,et al.  IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients , 2017, Oncoimmunology.

[3]  A. Boddy,et al.  Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis , 2017, Pigment cell & melanoma research.

[4]  Ronald D. Vale,et al.  T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition , 2016, Science.

[5]  K. Arihiro,et al.  h‐Prune is associated with poor prognosis and epithelial–mesenchymal transition in patients with colorectal liver metastases , 2016, International journal of cancer.

[6]  Antonio D’Avino,et al.  Il farmacista nella gestione delle sperimentazioni cliniche: analisi delle sperimentazioni farmacologiche condotte dal 2011 al 2014 all’ INT. G. Pascale , 2016 .

[7]  I. Osman,et al.  Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets , 2016, The Journal of Immunology.

[8]  A. Ohta.  A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment , 2016, Front. Immunol..

[9]  Gary K. Schwartz,et al.  Tumour exosome integrins determine organotropic metastasis , 2015, Nature.

[10]  Correction to “Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli” , 2015, Pharmacological Reviews.

[11]  P. Callaghan,et al.  The Experience of Melanoma Follow-Up Care: An Online Survey of Patients in Australia , 2014, Journal of skin cancer.

[12]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[13]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[14]  R. Zamoyska,et al.  Ligand engaged TCR is triggered by Lck not associated with CD8 coreceptor , 2014, Nature Communications.

[15]  A. Ribas,et al.  Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. , 2014, The Lancet. Oncology.

[16]  G. Chiappetta,et al.  H-Prune through GSK-3β interaction sustains canonical WNT/β-catenin signaling enhancing cancer progression in NSCLC , 2014, Oncotarget.

[17]  T. Crook,et al.  Electronic Sculpting of Ligand-GPCR Subtype Selectivity: The Case of Angiotensin II , 2014, ACS chemical biology.

[18]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Ascierto,et al.  The cost of unresectable stage III or stage IV melanoma in Italy , 2012, Journal of experimental & clinical cancer research : CR.

[20]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[21]  A. Levy,et al.  Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). , 2012, European journal of cancer.

[22]  A. Baker,et al.  Serum microRNAs as biomarkers for recurrence in melanoma , 2012, Journal of Translational Medicine.

[23]  D. Morton,et al.  AIM1 and LINE-1 Epigenetic Aberrations In Tumor and Serum Relate to Melanoma Progression and Disease Outcome , 2012, The Journal of investigative dermatology.

[24]  F. Slack,et al.  MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy , 2011, Nature Reviews Cancer.

[25]  Y. Inoue,et al.  The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. , 2011, Journal of dermatological science.

[26]  B. Evavold,et al.  Two-stage cooperative T cell receptor-peptide major histocompatibility complex-CD8 trimolecular interactions amplify antigen discrimination. , 2011, Immunity.

[27]  T. Lakshmikanth,et al.  New views on natural killer cell-based immunotherapy for melanoma treatment. , 2010, Trends in immunology.

[28]  Eckart Meese,et al.  High-throughput miRNA profiling of human melanoma blood samples , 2010, BMC Cancer.

[29]  Cheng Zhu,et al.  The kinetics of two dimensional TCR and pMHC interactions determine T cell responsiveness , 2010, Nature.

[30]  A. Baykov,et al.  Human metastasis regulator protein H-prune is a short-chain exopolyphosphatase. , 2008, Biochemistry.

[31]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[32]  S. Miura,et al.  Constitutively Active Homo-oligomeric Angiotensin II Type 2 Receptor Induces Cell Signaling Independent of Receptor Conformation and Ligand Stimulation* , 2005, Journal of Biological Chemistry.

[33]  L. Aravind,et al.  Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis. , 2004, Cancer cell.

[34]  J. Kenealy,et al.  A 6 year prospective analysis of the diagnosis of malignant melanoma in a pigmented-lesion clinic: even the experts miss malignant melanomas, but not often. , 2001, British journal of plastic surgery.

[35]  H. Varmus,et al.  Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer , 2000, Oncogene.

[36]  E. Evans,et al.  Sensitive force technique to probe molecular adhesion and structural linkages at biological interfaces. , 1995, Biophysical journal.

[37]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[38]  N. Kasparian.  Psychological stress and melanoma: are we meeting our patients' psychological needs? , 2013, Clinics in dermatology.

[39]  A. Cossu,et al.  Overexpression of h-prune in breast cancer is correlated with advanced disease status. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  R. Sanson-Fisher,et al.  The unmet supportive care needs of patients with cancer , 2000, Cancer.